The impact of antileukotriene therapy on markers of airway inflammation

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Asthma is a chronic, persistent inflammatory condition modulated by a variety of inflammatory cells and mediators. The current 'gold standard' asthma maintenance medication is an inhaled corticosteroid, which controls asthma via its anti-inflammatory effects in the airway. In order to be successful, new controller medications must have the ability to block infiltration and activation of inflammatory cells in the airway. Antileukotriene agents, such as the cysteinyl leukotriene receptor antagonist zafirlukast ('Accolate'), show these effects following allergen challenge in the lung. Forty-eight hours after segmental allergen challenge (SAC), bronchoalveolar lavage (BAL) fluid recovered from patients administered zafirlukast (20 mg b.i.d.), showed significantly lower concentrations of basophils and histamine than that from patients who received placebo (p < 0.01), and significantly lower superoxide production from purified alveolar macrophages (p < 0.01). In a subsequent study, zafirlukast (160 mg b.i.d.) significantly reduced the number of basophils and eosinophils in BAL fluid 48 h after SAC. Spontaneous superoxide release from alveolar macrophages was also significantly reduced by zafirlukast. Studies with other antileukotriene agents, such as the 5-lipoxygenase inhibitor zileuton, have demonstrated decreased eosinophilia in BAL fluid following allergen challenge and in patients with nocturnal asthma. Collectively, these data suggest that cysteinyl leukotrienes amplify inflammation, and that antileukotriene agents can reduce airway inflammation in asthma.

Original languageEnglish (US)
Pages (from-to)374-377
Number of pages4
JournalEuropean Respiratory Review
Volume8
Issue number60
StatePublished - 1998
Externally publishedYes

Fingerprint

Asthma
Allergens
Inflammation
Bronchoalveolar Lavage Fluid
Basophils
Alveolar Macrophages
zileuton
Superoxides
Leukotriene Antagonists
Therapeutics
Lipoxygenase Inhibitors
Eosinophilia
Eosinophils
Histamine
Adrenal Cortex Hormones
Anti-Inflammatory Agents
Placebos
Maintenance
zafirlukast
Lung

Keywords

  • Anti-inflammatory
  • Antileukotrienes
  • Asthma
  • Eosinophils
  • Inflammation
  • Zafirlukast

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

The impact of antileukotriene therapy on markers of airway inflammation. / Calhoun, William.

In: European Respiratory Review, Vol. 8, No. 60, 1998, p. 374-377.

Research output: Contribution to journalArticle

@article{19cd1fc37b0545de8ff90d11356996ca,
title = "The impact of antileukotriene therapy on markers of airway inflammation",
abstract = "Asthma is a chronic, persistent inflammatory condition modulated by a variety of inflammatory cells and mediators. The current 'gold standard' asthma maintenance medication is an inhaled corticosteroid, which controls asthma via its anti-inflammatory effects in the airway. In order to be successful, new controller medications must have the ability to block infiltration and activation of inflammatory cells in the airway. Antileukotriene agents, such as the cysteinyl leukotriene receptor antagonist zafirlukast ('Accolate'), show these effects following allergen challenge in the lung. Forty-eight hours after segmental allergen challenge (SAC), bronchoalveolar lavage (BAL) fluid recovered from patients administered zafirlukast (20 mg b.i.d.), showed significantly lower concentrations of basophils and histamine than that from patients who received placebo (p < 0.01), and significantly lower superoxide production from purified alveolar macrophages (p < 0.01). In a subsequent study, zafirlukast (160 mg b.i.d.) significantly reduced the number of basophils and eosinophils in BAL fluid 48 h after SAC. Spontaneous superoxide release from alveolar macrophages was also significantly reduced by zafirlukast. Studies with other antileukotriene agents, such as the 5-lipoxygenase inhibitor zileuton, have demonstrated decreased eosinophilia in BAL fluid following allergen challenge and in patients with nocturnal asthma. Collectively, these data suggest that cysteinyl leukotrienes amplify inflammation, and that antileukotriene agents can reduce airway inflammation in asthma.",
keywords = "Anti-inflammatory, Antileukotrienes, Asthma, Eosinophils, Inflammation, Zafirlukast",
author = "William Calhoun",
year = "1998",
language = "English (US)",
volume = "8",
pages = "374--377",
journal = "European Respiratory Review",
issn = "0905-9180",
publisher = "European Respiratory Society",
number = "60",

}

TY - JOUR

T1 - The impact of antileukotriene therapy on markers of airway inflammation

AU - Calhoun, William

PY - 1998

Y1 - 1998

N2 - Asthma is a chronic, persistent inflammatory condition modulated by a variety of inflammatory cells and mediators. The current 'gold standard' asthma maintenance medication is an inhaled corticosteroid, which controls asthma via its anti-inflammatory effects in the airway. In order to be successful, new controller medications must have the ability to block infiltration and activation of inflammatory cells in the airway. Antileukotriene agents, such as the cysteinyl leukotriene receptor antagonist zafirlukast ('Accolate'), show these effects following allergen challenge in the lung. Forty-eight hours after segmental allergen challenge (SAC), bronchoalveolar lavage (BAL) fluid recovered from patients administered zafirlukast (20 mg b.i.d.), showed significantly lower concentrations of basophils and histamine than that from patients who received placebo (p < 0.01), and significantly lower superoxide production from purified alveolar macrophages (p < 0.01). In a subsequent study, zafirlukast (160 mg b.i.d.) significantly reduced the number of basophils and eosinophils in BAL fluid 48 h after SAC. Spontaneous superoxide release from alveolar macrophages was also significantly reduced by zafirlukast. Studies with other antileukotriene agents, such as the 5-lipoxygenase inhibitor zileuton, have demonstrated decreased eosinophilia in BAL fluid following allergen challenge and in patients with nocturnal asthma. Collectively, these data suggest that cysteinyl leukotrienes amplify inflammation, and that antileukotriene agents can reduce airway inflammation in asthma.

AB - Asthma is a chronic, persistent inflammatory condition modulated by a variety of inflammatory cells and mediators. The current 'gold standard' asthma maintenance medication is an inhaled corticosteroid, which controls asthma via its anti-inflammatory effects in the airway. In order to be successful, new controller medications must have the ability to block infiltration and activation of inflammatory cells in the airway. Antileukotriene agents, such as the cysteinyl leukotriene receptor antagonist zafirlukast ('Accolate'), show these effects following allergen challenge in the lung. Forty-eight hours after segmental allergen challenge (SAC), bronchoalveolar lavage (BAL) fluid recovered from patients administered zafirlukast (20 mg b.i.d.), showed significantly lower concentrations of basophils and histamine than that from patients who received placebo (p < 0.01), and significantly lower superoxide production from purified alveolar macrophages (p < 0.01). In a subsequent study, zafirlukast (160 mg b.i.d.) significantly reduced the number of basophils and eosinophils in BAL fluid 48 h after SAC. Spontaneous superoxide release from alveolar macrophages was also significantly reduced by zafirlukast. Studies with other antileukotriene agents, such as the 5-lipoxygenase inhibitor zileuton, have demonstrated decreased eosinophilia in BAL fluid following allergen challenge and in patients with nocturnal asthma. Collectively, these data suggest that cysteinyl leukotrienes amplify inflammation, and that antileukotriene agents can reduce airway inflammation in asthma.

KW - Anti-inflammatory

KW - Antileukotrienes

KW - Asthma

KW - Eosinophils

KW - Inflammation

KW - Zafirlukast

UR - http://www.scopus.com/inward/record.url?scp=0031715521&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031715521&partnerID=8YFLogxK

M3 - Article

VL - 8

SP - 374

EP - 377

JO - European Respiratory Review

JF - European Respiratory Review

SN - 0905-9180

IS - 60

ER -